Skip to search formSkip to main contentSkip to account menu

trastuzumab

Known as: Anti-p185-HER2, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-c-ERB-2 
A monoclonal antibody that binds to HER2 (human epidermal growth factor receptor 2), and can kill HER2-positive cancer cells. Monoclonal antibodies… 
National Institutes of Health

Related topics

Related topics

21 relations

Narrower (3)

ABP 980HerceptinPF-05280014
AC-T-T RegimenAntibody-Dependent Cellular CytotoxicityDrug AllergyERBB2 protein, human
Expand

Broader (1)

Antineoplastic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
BACKGROUND Pembrolizumab is a humanized monoclonal antibody against programmed death 1 (PD-1) that has antitumor activity in… 
Review
2012
Review
2012
Trastuzumab emtansine for HER2-positive advanced breast cancer.
BACKGROUND Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate incorporating the human epidermal growth factor receptor 2… 
Highly Cited
2011
Highly Cited
2011
Adjuvant trastuzumab in HER2-positive breast cancer.
BACKGROUND Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with… 
Review
2007
Review
2007
Trastuzumab--mechanism of action and use in clinical practice.
  • C. Hudis
  • The New England journal of medicine
  • 2007
  • Corpus ID: 10626776
Overexpression of human epidermal growth factor receptor type 2 (HER2) in breast cancer is associated with decreased overall… 
Highly Cited
2006
Highly Cited
2006
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
BACKGROUND We conducted a multinational, randomized study to compare radiotherapy alone with radiotherapy plus cetuximab, a… 
Highly Cited
2005
Highly Cited
2005
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
BACKGROUND We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent… 
Highly Cited
2005
Highly Cited
2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
BACKGROUND Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that… 
Review
2005
Review
2005
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
Highly Cited
2002
Highly Cited
2002
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
PURPOSE To evaluate the efficacy and safety of first-line, single-agent trastuzumab in women with HER2-overexpressing metastatic… 
Highly Cited
2002
Highly Cited
2002
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
Background The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License